We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Albuminuria as a surrogate marker for drug development: A European Regulatory perspective.
- Authors
Calvo, Gonzalo; De Andres-Trelles, Fernando
- Abstract
Albuminuria as a surrogate marker for drug development: A European Regulatory perspective. Clinical trials with surrogate end points generally require smaller sample sizes and shorter duration than those with clinical outcomes. However, in practice, surrogate end points are likely to result in less comprehensive conclusions than‘outcome’ end points as they sometimes reflect only partial aspects of complex phenomena. A number of conditions help to establish the validity of a particular variable as predictive of clinical outcome. This article discusses to what extent albuminuria fulfills these requisites in two particular clinical scenarios: prevention of renal deterioration and prevention of cardiovascular disease.
- Subjects
EUROPE; ALBUMINURIA; KIDNEY diseases; BIOMARKERS; CARDIOVASCULAR disease prevention; DRUG development; PHARMACEUTICAL policy
- Publication
Kidney International Supplement, 2004, Issue 92, pS126
- ISSN
0098-6577
- Publication type
Article
- DOI
10.1111/j.1523-1755.2004.09232.x